Key result
Giant cell myocarditis predicts ~168% greater risk of death or transplantation versus cardiac sarcoidosis.
Why the study?
Incidental cases of giant cell myocarditis converted to cardiac sarcoidosis at post-transplant or post-mortem examinations prompted a re-evaluation of national giant cell myocarditis diagnoses.
Population
46 patients diagnosed with GCM since 1991 in Finland
Comparison
Patients reclassified as CS vs patients keeping GCM diagnosis
Design
Re-evaluation of a previously reported cohort
Follow-up
5 years
Authors
Loading...
Confirmed giant cell myocarditis signals high death or transplant risk; leaves open refined incidence and outcomes after sarcoidosis reclassification.
Hazard Ratio: 2.68 (95% CI 1.22–5.87)
p-value: p=0.014
Re-evaluation of a historical giant cell myocarditis cohort revealed that over half of the cases were actually cardiac sarcoidosis, and true giant cell myocarditis has a significantly worse 5-year transplant-free survival (25%) than previously estimated.
Ekström et al. (2020) conducted a letter in Giant cell myocarditis and cardiac sarcoidosis (n=46). Giant cell myocarditis vs. Cardiac sarcoidosis was evaluated on Death or transplantation (HR 2.68, 95% CI 1.22-5.87, p=0.014). A confirmed diagnosis of giant cell myocarditis predicted the occurrence of death or transplantation with a hazard ratio of 2.68 (95% CI 1.22-5.87; P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: